AxoGen posts Q4 loss as FDA regulatory costs hit margins

AxoGen

24/02/2026 12:17

Overview

Surgical solutions provider's Q4 revenue grew 21.3% yr/yr

Company reported a net loss of $13.2 mln for Q4 2025, vs net income a year earlier

Gross margin decreased due to one-time FDA approval costs

Outlook

AxoGen expects 2026 revenue growth of at least 18%, reaching $265.7 mln

Company anticipates 2026 gross margin between 74% and 76%

AxoGen projects to be free cash flow positive for full-year 2026

Result Drivers

BROAD-BASED REVENUE GROWTH - Co reported double-digit growth across all markets, including Extremities, Oral Maxillofacial & Head and Neck, and Breast

FDA APPROVAL COSTS - Gross margin impacted by one-time costs related to FDA approval of Avance®

EXPANDED COVERAGE - Co expanded coverage and reimbursement for peripheral nerve repair, increasing newly covered lives and commercial payer coverage

Company press release: ID:nGNX7t2RC8

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$13.20 mln
Q4 Adjusted EBITDA
$6.50 mln
Q4 Gross Margin
74.10%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for AxoGen Inc is $40.00, about 13.1% above its February 23 closing price of $35.38

The stock recently traded at 70 times the next 12-month earnings vs. a P/E of 49 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)